RE:RE:RE:RE:US LISTINGAlthough I’ve used ONC in my example of possible share consolidation scenarios, I don’t think it’s an apples to apples situation here with DMA. I really like DMA because they have shown( fingers crossed) that what they have replaces another drug already on the market as well as possible other indications where this drug could be applicable too. What I was hoping is that we would see positive results out of Australia before they proceed with the share consolidation... One thing for sure, is that the stock may become very illiquid after the consolidation and that may hurt (or help- depending on results) the share price like we are seeing with ONC as they wait on news. One other thing, I thought this Chinese licensing deal would have propelled the stock much higher than what the share price is currently sitting at — and my thought is that management thought the same as well... interesting times that’s for sure!!!
Cheers. JL